The effective use of agents that inhibit ErB4 in brain cancer will require research that identifies pro-tumorigenic forms of ErbB4; targeting tumor suppressor forms of ErbB4 with drugs could obviously be detrimental to patients. Here, ERBB4 is linked to brain cancer.